Gain Therapeutics (GANX) Institutional Ownership → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free GANX Stock Alerts $3.03 -0.04 (-1.30%) (As of 04/26/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Gain Therapeutics (NASDAQ:GANX)CurrentInstitutional OwnershipPercentage11.97%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$60.03KNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$159.21K Get GANX Insider Trade Alerts Want to know when executives and insiders are buying or selling Gain Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data GANX Institutional Buying and Selling by Quarter Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. Gain Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails1/16/2024 Raymond James & Associates23,788$78K0.0%-29.6%0.184% 7/25/2023 Raymond James & Associates33,400$150K0.0%+67.0%0.271% 5/8/2023CM Management LLC90,000$434K0.5%-18.2%0.740% 5/2/2023 Wealth Alliance Advisory Group LLC12,502$60K0.0%-33.3%0.105% 4/14/2023 Raymond James & Associates20,000$96K0.0%-16.7%0.168% 2/9/2023CM Management LLC110,000$344K0.4%-12.0%0.926% Get the Latest News and Ratings for GANX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/17/2023 Wealth Alliance Advisory Group LLC18,751$59K0.0%-25.0%0.158% 11/17/2022Telemetry Investments L.L.C.150,000$489K0.6%-6.3%1.263% 10/25/2022 Raymond James & Associates24,000$78K0.0%N/A0.202% 10/12/2022 Wealth Alliance Advisory Group LLC25,000$82K0.0%N/A0.210% 5/9/2022CM Management LLC125,000$511K0.4%+38.9%1.052% 2/3/2022Advisor Group Holdings Inc.10,050$54K0.0%N/A0.085% 2/2/2022CM Management LLC90,000$489K0.4%+39.9%0.758% 11/16/2021Telemetry Investments L.L.C.96,232$716K1.0%+217.7%0.810% 11/15/2021Veritable L.P.25,064$187K0.0%N/A0.211% 11/9/2021Indie Asset Partners LLC29,652$221K0.2%N/A0.250% 11/8/2021CM Management LLC64,327$479K0.4%+543.3%0.542% 8/17/2021Bridgeway Capital Management LLC50,000$501K0.0%N/A0.421% 8/16/2021Telemetry Investments L.L.C.30,293$303K0.4%N/A0.255% 8/11/2021 Banque Cantonale Vaudoise3,000$30K0.0%N/A0.025% 8/10/2021CM Management LLC10,000$100K0.1%N/A0.084% 5/27/2021Davidson Kempner Capital Management LP15,000$222K0.0%N/A0.126% 5/19/2021Worth Venture Partners LLC15,532$232K0.1%N/A0.131% 5/18/2021Millennium Management LLC14,367$214K0.0%N/A0.121% 5/18/2021Greenlight Capital Inc.546,560$8.16M0.6%N/A4.602% 5/18/2021Davidson Kempner Capital Management LP15,000$222K0.0%N/A0.126% 5/18/2021Jane Street Group LLC22,754$339K0.0%N/A0.192% (Data available from 1/1/2016 forward) GANX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of GANX shares? During the previous two years, the following institutional investors and hedge funds held shares of Gain Therapeutics shares: Telemetry Investments L.L.C. ($489K), CM Management LLC ($434K), and Raymond James & Associates ($78K), Wealth Alliance Advisory Group LLC ($60K).Learn more on GANX's institutional investors. What percentage of Gain Therapeutics stock is owned by institutional investors? 11.97% of Gain Therapeutics stock is owned by institutional investors. Learn more on GANX's institutional investor holdings. Which institutional investors have been buying Gain Therapeutics stock? The following institutional investors have purchased Gain Therapeutics stock in the last 24 months: Raymond James & Associates ($37.40K), CM Management LLC ($35K), and Wealth Alliance Advisory Group LLC ($25K). How much institutional buying is happening at Gain Therapeutics? Institutional investors have bought a total of 97,400 shares in the last 24 months. This purchase volume represents approximately $362.92K in transactions. Which Gain Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Gain Therapeutics stock in the last 24 months: CM Management LLC ($35K), Raymond James & Associates ($14.01K), Wealth Alliance Advisory Group LLC ($12.50K), and Telemetry Investments L.L.C. ($10K). How much institutional selling is happening at Gain Therapeutics? Institutional investors have sold a total of 71,510 shares in the last 24 months. This volume of shares sold represents approximately $277.60K in transactions. Related Companies: Homology Medicines Major Shareholders Reneo Pharmaceuticals Major Shareholders Eledon Pharmaceuticals Major Shareholders Kronos Bio Major Shareholders SCYNEXIS Major Shareholders Checkpoint Therapeutics Major Shareholders BioLineRx Major Shareholders Kezar Life Sciences Major Shareholders Equillium Major Shareholders HCW Biologics Major Shareholders This page (NASDAQ:GANX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.